-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FJhGTl+S64Lwq2nHO8bKfvH67bL7sVSAnBqHK3CtIslXQ59Cnc/U2/9q/uJLkIWn 9AiTlx6s0GIHt04nWxEoWQ== 0001144204-09-042700.txt : 20090813 0001144204-09-042700.hdr.sgml : 20090813 20090813134935 ACCESSION NUMBER: 0001144204-09-042700 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20090630 FILED AS OF DATE: 20090813 DATE AS OF CHANGE: 20090813 EFFECTIVENESS DATE: 20090813 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RA CAPITAL MANAGEMENT, LLC CENTRAL INDEX KEY: 0001346824 IRS NUMBER: 830406777 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-12884 FILM NUMBER: 091009723 BUSINESS ADDRESS: STREET 1: 800 BOYLSTON STREET, SUITE 1500 CITY: BOSTON STATE: MA ZIP: 02199 BUSINESS PHONE: 617-778-2500 MAIL ADDRESS: STREET 1: 800 BOYLSTON STREET, SUITE 1500 CITY: BOSTON STATE: MA ZIP: 02199 13F-HR 1 v157705_13fhr.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 13F FORM 13F COVER PAGE Report for the Calendar Year or Quarter Ended: June 30, 2009 Check here if Amendment [ ]; Amendment Number: ___________ This Amendment (Check only one): [ ] is a restatement. [ ] adds new entries. Institutional Investment Manager Filing this Report: Name: RA Capital Management, LLC ------------------------------------- Address: 800 Boylston Street, Suite 1500 ------------------------------------- Boston, MA 02199 ------------------------------------- Form 13F File Number: 28-12884 -------- The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: Peter Kolchinsky ------------------------------------- Title: Manager ------------------------------------- Phone: (617) 778-2500 ------------------------------------- Signature, Place, and Date of Signing /s/ Peter Kolchinsky Boston, MA August 13, 2009 - -------------------------- -------------------------- ---------------------- [Signature] [City, State] [Date] Report Type (Check only one): [X] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.) [ ] 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).) [ ] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).) List of Other Managers Reporting for this Manager: NONE FORM 13F SUMMARY PAGE Report Summary: Number of Other Included Managers: 0 ----------------- Form 13F Information Tabel Entry Total: 18 ----------------- Form 13F Information Table Value Total: 113,433 ----------------- (thousands) List of Other Included Managers: NONE FORM 13F INFORMATION TABLE
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8 - ---------------------------- --------- ----------- -------- ------------------------- ---------- -------- --------------------- TITLE OF VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY NAME OF ISSUER CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE/ SHARED/NONE - ------------------------------------------------------------------------------------------------------------------------------------ ALEXION PHARMACEUTICALS INC COM 015351 10 9 6,989 170,000 SH SOLE N/A 170,000 ALLOS THERAPEUTICS INC COM 019777 10 1 829 100,000 SH SOLE N/A 100,000 AMAG PHARMACEUTICALS INC COM 00163U 10 6 3,280 60,000 SH SOLE N/A 60,000 ARDEA BIOSCIENCES INC COM 03969P 10 7 15,499 984,670 SH SOLE N/A 984,670 BIOMARIN PHARMACEUTICAL INC COM 09061G 10 1 3,903 250,000 SH SOLE N/A 250,000 CONCEPTUS INC COM 206016 10 7 761 45,000 SH SOLE N/A 45,000 CUBIST PHARMACEUTICALS INC COM 229678 10 7 5,504 300,260 SH SOLE N/A 300,260 DENDREON CORP COM 24823Q 10 7 10,026 401,040 SH SOLE N/A 401,040 ENTEROMEDICS INC COM 29365M 10 9 1,156 347,119 SH SOLE N/A 347,119 GENZYME CORP COM 372917 10 4 5,289 95,000 SH SOLE N/A 95,000 GILEAD SCIENCES INC COM 375558 10 3 16,862 360,000 SH SOLE N/A 360,000 OREXIGEN THERAPEUTICS INC COM 686164 10 4 1,166 227,300 SH SOLE N/A 227,300 OSI PHARMACEUTICALS INC COM 671040 10 3 988 35,000 SH SOLE N/A 35,000 PHARMASSET INC COM 71715N 10 6 7,162 636,658 SH SOLE N/A 636,658 SEQUENOM INC COM 817337 40 5 8,097 2,070,800 SH CALL SOLE N/A N/A UNITED THERAPEUTICS CORP DEL COM 91307C 10 2 7,500 90,000 SH SOLE N/A 90,000 VARIAN MED SYS INC COM 92220P 10 5 6,150 175,000 SH SOLE N/A 175,000 VERTEX PHARMACEUTICALS INC COM 92532F 10 0 12,275 341,244 SH SOLE N/A 341,244
-----END PRIVACY-ENHANCED MESSAGE-----